CYCC - サイクラセル・ファ―マシュ―ティカルズ (Cyclacel Pharmaceuticals Inc.) サイクラセル・ファ―マシュ―ティカルズ

 CYCCのチャート


 CYCCの企業情報

symbol CYCC
会社名 Cyclacel Pharmaceuticals Inc (サイクラセル・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 サイクラセル・ファーマシューティカルズ(Cyclacel Pharmaceuticals Inc.)は開発段階にあるバイオ製薬企業であり、ヒト癌とその他重篤な疾患を治療するメカニズムをターゲットとした医薬品の発見・開発・商業化に従事する。同社は米国とイギリスの2つの地域において開発事業を行う。同社はサパシタビン(sapacitabine)とセリシクリブ(seliciclib)が含まれる細胞周期に作用する複数の抗癌剤シリーズを生成している。同社は主に細胞周期の進行を減速したり、腫瘍のサーズを小さくしたりすることを目的とする、経口投与可能な抗癌剤の開発を中心とする。同社の臨床開発は高齢者急性骨髄性白血病(AML)、骨髄異形成症候群(MDS)及び非小細胞肺癌(NSCLC)を含むサパシタビンを中心としている。同社は癌とその他重篤な疾患を治療するため、細胞周期制御における様々な段階をターゲットとする低分子薬の開発・商業化を行う。   サイクラセル・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、がん及びその他重症疾患向け治療薬の開発・商品化に従事する。経口投与可能で、細胞分裂を抑止する小分子治験薬のパイプラインを推進する。主力候補薬には、急性骨髄性白血病治療薬の「Sapacitabine」がある。本社はニュ―ジャ―ジ―州。   
本社所在地 200 Connell Drive Suite 1500 Berkeley Heights NJ 07922 USA
代表者氏名 David Charles U'Prichard デビッドチャールズウプリアード
代表者役職名 Independent Chairman of the Board
電話番号 +1 908-517-7330
設立年月日 35065
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 16人
url www.cyclacel.com
nasdaq_url https://www.nasdaq.com/symbol/cycc
adr_tso
EBITDA EBITDA(百万ドル) -8.90700
終値(lastsale) 1.39
時価総額(marketcap) 16676451.33
時価総額 時価総額(百万ドル) 16.31653
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) -3.50747
当期純利益 当期純利益(百万ドル) -14.30400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cyclacel Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders decreased 14% to $3.3M. Lower net loss reflects Research and Development - other decrease of 24% to $1.9M (expense) Interest income increase from $30K to $153K (income) Stock-based Compensation in SGA decrease of 14% to $85K (expense). Dividend per share remained flat at $0.15.

 CYCCのテクニカル分析


 CYCCのニュース

   Cyclacel Pharmaceuticals (NASDAQ:CYCC) Upgraded to Hold at Zacks Investment Research  2020/11/20 08:06:48 Transcript Daily
Zacks Investment Research upgraded shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) from a sell rating to a hold rating in a research note issued to investors on Monday, Zacks.com reports. According to Zacks, “CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. […]
   Cyclacel Pharmaceuticals to Release Third Quarter Financial Results - Stocks News Feed  2020/11/05 14:29:12 Stocks News Feed
BERKELEY HEIGHTS, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2020 financial results on Wednesday, November 11, 2020. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on… Read More »Cyclacel Pharmaceuticals to Release Third Quarter Financial Results
   The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study  2020/09/04 11:28:02 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3) Akouos Inc (NASDAQ: AKUS ) FibroGen Inc (NASDAQ: FGEN )(reacted to an adverse clinical readout for a rival drug to treat chronic kidney disease related anemia) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Sutro Biopharma Inc (NASDAQ: STRO ) ( reacted to announcement concerning presentation of positive data for ovarian cancer drug) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 3) Akebia Therapeutics Inc (NASDAQ: AKBA ) (announced negative safety results for a late-stage study of drug to treat chronic kidney disease-induced anemia) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Genfit SA (NASDAQ: GNFT ) Gritstone Oncology Inc (NASDAQ: GRTS ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Homology Medicines Inc (NASDAQ: FIXX ) Immatics NV (NASDAQ: IMTX ) Interpace Biosciences Inc (NASDAQ: IDXG ) Jaguar Health Inc (NASDAQ: JAGX ) Legend Biotech Corp (NASDAQ: LEGN ) Monopar Therapeutics Inc (NASDAQ: MNPR ) NanoVibronix Inc (NASDAQ: NAOV ) Odonate Therapeutics Inc (NASDAQ: ODT ) RA Medical Systems Inc (NYSE: RMED ) Recro Pharma Inc (NASDAQ: REPH ) Rockwell Medical Inc (NASDAQ: RMTI ) Soliton Inc (NASDAQ: SOLY ) Sun BioPharma, Inc. (NASDAQ: SNBP ) Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) Teligent Inc (NASDAQ: TLGT ) Related Link: Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates Stocks In Focus Lilly Gets FDA Nod For 2 Higher Doses of Its Best-selling Diabetes Drug Eli Lilly And Co (NYSE: LLY ) said the FDA approved two additional doses of its Type 2 diabetes drug Trulicity.
   The Daily Biotech Pulse: Sanofi, GSK Begin Phase 1/2 Coronavirus Vaccine Study, Fulgent Strikes COVID-19 Testing Deal, New Data From Novavax  2020/09/03 11:55:02 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Acutus Medical Inc (NASDAQ: AFIB ) Akouos Inc (NASDAQ: AKUS ) Avid Bioservices Inc (NASDAQ: CDMO ) ( reacted to strong quarterly results) BioLife Solutions Inc (NASDAQ: BLFS ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Edwards Lifesciences Corp (NYSE: EW ) Evogene Ltd (NASDAQ: EVGN ) Fortress Biotech (NASDAQ: FBIO ) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) (priced its 5.27-million-share common stock offering at $33 per share) Inspire Medical Systems Inc (NYSE: INSP ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Silk Road Medical Inc (NASDAQ: SILK ) Shockwave Medical Inc (NASDAQ: SWAV ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Twist Bioscience Corp (NASDAQ: TWST ) (announced potent SARS-CoV-2 neutralizing data from COVID-19 therapeutic antibody program) West Pharmaceutical Services Inc. (NYSE: WST ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 2) Acorda Therapeutics Inc (NASDAQ: ACOR ) ADiTx Therapeutics Inc (NASDAQ: ADTX ) (priced a $9.6-million follow-on offering) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Entera Bio Ltd (NASDAQ: ENTX ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Gritstone Oncology Inc (NASDAQ: GRTS ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Histogen Inc (NASDAQ: HSTO ) Interpace Biosciences Inc (NASDAQ: IDXG ) Iterum Therapeutics PLC (NASDAQ: ITRM ) NanoVibronix Inc (NASDAQ: NAOV ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Nkarta Inc (NASDAQ: NKTX ) Oncternal Therapeutics Inc (NASDAQ: ONCT ) Psychemedics Corp. (NASDAQ: PMD ) Rockwell Medical Inc (NASDAQ: RMTI ) Sun BioPharma, Inc. (NASDAQ: SNBP ) Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) Stocks In Focus Sutro To Present Positive Phase 1 Ovarian Cancer Data In an abstract submitted to the International Gynecologic Cancer Society …
   Cyclacel Pharmaceuticals Reports Second Quarter 2020 Financial Results  2020/08/12 20:05:00 GlobeNewswire
- Conference Call Scheduled August 12, 2020 at 4:30 p.m. ET -
   Cyclacel Pharmaceuticals (NASDAQ:CYCC) Upgraded to Hold at Zacks Investment Research  2020/11/20 08:06:48 Transcript Daily
Zacks Investment Research upgraded shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) from a sell rating to a hold rating in a research note issued to investors on Monday, Zacks.com reports. According to Zacks, “CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. […]
   Cyclacel Pharmaceuticals to Release Third Quarter Financial Results - Stocks News Feed  2020/11/05 14:29:12 Stocks News Feed
BERKELEY HEIGHTS, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2020 financial results on Wednesday, November 11, 2020. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on… Read More »Cyclacel Pharmaceuticals to Release Third Quarter Financial Results
   The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study  2020/09/04 11:28:02 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3) Akouos Inc (NASDAQ: AKUS ) FibroGen Inc (NASDAQ: FGEN )(reacted to an adverse clinical readout for a rival drug to treat chronic kidney disease related anemia) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Sutro Biopharma Inc (NASDAQ: STRO ) ( reacted to announcement concerning presentation of positive data for ovarian cancer drug) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 3) Akebia Therapeutics Inc (NASDAQ: AKBA ) (announced negative safety results for a late-stage study of drug to treat chronic kidney disease-induced anemia) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Genfit SA (NASDAQ: GNFT ) Gritstone Oncology Inc (NASDAQ: GRTS ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Homology Medicines Inc (NASDAQ: FIXX ) Immatics NV (NASDAQ: IMTX ) Interpace Biosciences Inc (NASDAQ: IDXG ) Jaguar Health Inc (NASDAQ: JAGX ) Legend Biotech Corp (NASDAQ: LEGN ) Monopar Therapeutics Inc (NASDAQ: MNPR ) NanoVibronix Inc (NASDAQ: NAOV ) Odonate Therapeutics Inc (NASDAQ: ODT ) RA Medical Systems Inc (NYSE: RMED ) Recro Pharma Inc (NASDAQ: REPH ) Rockwell Medical Inc (NASDAQ: RMTI ) Soliton Inc (NASDAQ: SOLY ) Sun BioPharma, Inc. (NASDAQ: SNBP ) Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) Teligent Inc (NASDAQ: TLGT ) Related Link: Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates Stocks In Focus Lilly Gets FDA Nod For 2 Higher Doses of Its Best-selling Diabetes Drug Eli Lilly And Co (NYSE: LLY ) said the FDA approved two additional doses of its Type 2 diabetes drug Trulicity.
   The Daily Biotech Pulse: Sanofi, GSK Begin Phase 1/2 Coronavirus Vaccine Study, Fulgent Strikes COVID-19 Testing Deal, New Data From Novavax  2020/09/03 11:55:02 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Acutus Medical Inc (NASDAQ: AFIB ) Akouos Inc (NASDAQ: AKUS ) Avid Bioservices Inc (NASDAQ: CDMO ) ( reacted to strong quarterly results) BioLife Solutions Inc (NASDAQ: BLFS ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Edwards Lifesciences Corp (NYSE: EW ) Evogene Ltd (NASDAQ: EVGN ) Fortress Biotech (NASDAQ: FBIO ) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) (priced its 5.27-million-share common stock offering at $33 per share) Inspire Medical Systems Inc (NYSE: INSP ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Silk Road Medical Inc (NASDAQ: SILK ) Shockwave Medical Inc (NASDAQ: SWAV ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Twist Bioscience Corp (NASDAQ: TWST ) (announced potent SARS-CoV-2 neutralizing data from COVID-19 therapeutic antibody program) West Pharmaceutical Services Inc. (NYSE: WST ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 2) Acorda Therapeutics Inc (NASDAQ: ACOR ) ADiTx Therapeutics Inc (NASDAQ: ADTX ) (priced a $9.6-million follow-on offering) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Entera Bio Ltd (NASDAQ: ENTX ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Gritstone Oncology Inc (NASDAQ: GRTS ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Histogen Inc (NASDAQ: HSTO ) Interpace Biosciences Inc (NASDAQ: IDXG ) Iterum Therapeutics PLC (NASDAQ: ITRM ) NanoVibronix Inc (NASDAQ: NAOV ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Nkarta Inc (NASDAQ: NKTX ) Oncternal Therapeutics Inc (NASDAQ: ONCT ) Psychemedics Corp. (NASDAQ: PMD ) Rockwell Medical Inc (NASDAQ: RMTI ) Sun BioPharma, Inc. (NASDAQ: SNBP ) Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) Stocks In Focus Sutro To Present Positive Phase 1 Ovarian Cancer Data In an abstract submitted to the International Gynecologic Cancer Society …
   Cyclacel Pharmaceuticals Reports Second Quarter 2020 Financial Results  2020/08/12 20:05:00 GlobeNewswire
- Conference Call Scheduled August 12, 2020 at 4:30 p.m. ET -
   The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study  2020/09/04 11:28:02 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3) Akouos Inc (NASDAQ: AKUS ) FibroGen Inc (NASDAQ: FGEN )(reacted to an adverse clinical readout for a rival drug to treat chronic kidney disease related anemia) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Sutro Biopharma Inc (NASDAQ: STRO ) ( reacted to announcement concerning presentation of positive data for ovarian cancer drug) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 3) Akebia Therapeutics Inc (NASDAQ: AKBA ) (announced negative safety results for a late-stage study of drug to treat chronic kidney disease-induced anemia) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Genfit SA (NASDAQ: GNFT ) Gritstone Oncology Inc (NASDAQ: GRTS ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Homology Medicines Inc (NASDAQ: FIXX ) Immatics NV (NASDAQ: IMTX ) Interpace Biosciences Inc (NASDAQ: IDXG ) Jaguar Health Inc (NASDAQ: JAGX ) Legend Biotech Corp (NASDAQ: LEGN ) Monopar Therapeutics Inc (NASDAQ: MNPR ) NanoVibronix Inc (NASDAQ: NAOV ) Odonate Therapeutics Inc (NASDAQ: ODT ) RA Medical Systems Inc (NYSE: RMED ) Recro Pharma Inc (NASDAQ: REPH ) Rockwell Medical Inc (NASDAQ: RMTI ) Soliton Inc (NASDAQ: SOLY ) Sun BioPharma, Inc. (NASDAQ: SNBP ) Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) Teligent Inc (NASDAQ: TLGT ) Related Link: Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates Stocks In Focus Lilly Gets FDA Nod For 2 Higher Doses of Its Best-selling Diabetes Drug Eli Lilly And Co (NYSE: LLY ) said the FDA approved two additional doses of its Type 2 diabetes drug Trulicity.
   The Daily Biotech Pulse: Sanofi, GSK Begin Phase 1/2 Coronavirus Vaccine Study, Fulgent Strikes COVID-19 Testing Deal, New Data From Novavax  2020/09/03 11:55:02 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Acutus Medical Inc (NASDAQ: AFIB ) Akouos Inc (NASDAQ: AKUS ) Avid Bioservices Inc (NASDAQ: CDMO ) ( reacted to strong quarterly results) BioLife Solutions Inc (NASDAQ: BLFS ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Edwards Lifesciences Corp (NYSE: EW ) Evogene Ltd (NASDAQ: EVGN ) Fortress Biotech (NASDAQ: FBIO ) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) (priced its 5.27-million-share common stock offering at $33 per share) Inspire Medical Systems Inc (NYSE: INSP ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Silk Road Medical Inc (NASDAQ: SILK ) Shockwave Medical Inc (NASDAQ: SWAV ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Twist Bioscience Corp (NASDAQ: TWST ) (announced potent SARS-CoV-2 neutralizing data from COVID-19 therapeutic antibody program) West Pharmaceutical Services Inc. (NYSE: WST ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 2) Acorda Therapeutics Inc (NASDAQ: ACOR ) ADiTx Therapeutics Inc (NASDAQ: ADTX ) (priced a $9.6-million follow-on offering) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Entera Bio Ltd (NASDAQ: ENTX ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Gritstone Oncology Inc (NASDAQ: GRTS ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Histogen Inc (NASDAQ: HSTO ) Interpace Biosciences Inc (NASDAQ: IDXG ) Iterum Therapeutics PLC (NASDAQ: ITRM ) NanoVibronix Inc (NASDAQ: NAOV ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Nkarta Inc (NASDAQ: NKTX ) Oncternal Therapeutics Inc (NASDAQ: ONCT ) Psychemedics Corp. (NASDAQ: PMD ) Rockwell Medical Inc (NASDAQ: RMTI ) Sun BioPharma, Inc. (NASDAQ: SNBP ) Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) Stocks In Focus Sutro To Present Positive Phase 1 Ovarian Cancer Data In an abstract submitted to the International Gynecologic Cancer Society …
   Cyclacel Pharmaceuticals Reports Second Quarter 2020 Financial Results  2020/08/12 20:05:00 GlobeNewswire
- Conference Call Scheduled August 12, 2020 at 4:30 p.m. ET -
   Cyclacel Pharmaceuticals Investors Should Be Furious After This Move  2020/04/21 15:20:37 24/7 Wall street
   Nano-Cap Cyclacel Rockets Higher On Launch Of Study For Coronavirus Inflammation  2020/04/20 15:33:29 Benzinga
Shares of nanocap biopharma Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) were ripping higher Monday following the announcement of a partnership to study two of its drugs to treat complications arising from COVID-19. The company said it has entered into an agreement with the University of Edinburgh to study two of its pipeline assets — fadraciclib and seliciclib — as potential early treatments for the inflammatory response observed in patients with COVID-19 disease. Fadraciclib and seliciclib are both investigational CDK2/9 inhibitors in development. Cyclacel is studying the drugs for their suitability for use in safety and efficacy studies in COVID-19 patients. The … Full story available on Benzinga.com

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 サイクラセル・ファ―マシュ―ティカルズ CYCC Cyclacel Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)